surmount-1 trial tirzepatide obesity without diabetes weight loss lowers body for adults with obesity, regardless of disease duration Tirzepatide for maintenance of bodyweight
Description
Among the patients who discontinued tirzepatide, 29.1% re-initiated tirzepatide after the 45-day gap
00656-2/asset/38c98550-9ec2-44e8-ba6a-dbb815075666/main.assets/gr1_lrg.jpg)
Because the half-life is about 5 days and you dose weekly, blood levels rise for the first 4 weeks before stabilizing
01200-X/asset/f2ef2727-f32c-4146-a724-f0b9312e4d9f/main.assets/gr1_lrg.jpg)
This is the most meaningful single measurement for men on tirzepatide because visceral fat loss shows here first
If the dose prescribed is 12.5 mg/week or above, your monthly subscription price will increase by $100 each month
If a patient is stable and doing well, then they stay on that treatment
